4D Pharma, Merck And Pfizer Ink Trial Collaboration For Carcinoma Drug
4D Pharma, Merck And Pfizer Ink Trial Collaboration For Carcinoma Drug
Read more4D Pharma, Merck And Pfizer Ink Trial Collaboration For Carcinoma Drug
Read more(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced progress on activities in its development programme for its lead immuno-oncology single strain 'live biotherapeutic' candidate MRx0518 on Wednesday.
Read moreSMALL-CAP WINNERS & LOSERS: Dr Martens Puts Best Foot Forward
Read more4D Pharma Says MRx0518 Part B Study Enrolment Continues To Progress
Read more4D Pharma Joins Landmark Study For Parkinson's Treatment Development
Read more4D Pharma Files US Registration Statement For ADR Programme
Read moreIN BRIEF: 4d Pharma Reports Positive Data From Ongoing MRx051 Trials
Read moreIN BRIEF: 4D Pharma Proposes Merger With Longevity Acquisition
Read moreUK WINNERS & LOSERS SUMMARY: Shaftesbury Down 13% Amid Fundraise Plans
Read more4D Pharma Reports Positive Results From Bowel Syndrome Treatment Trial
Read moreIN BRIEF: 4D Pharma Interim Loss Widens On R&D Costs Increase
Read moreUK EXECUTIVE CHANGE SUMMARY: Primorus Adds Three Directors To Board
Read moreUK WINNERS & LOSERS SUMMARY: Provident Financial Up On Better Outlook
Read more4D Pharma Says Results In MRx0518, Keytruda Cancer Trial "Encouraging"
Read moreUK TRADING UPDATE SUMMARY: Mineral & Financial Invests In Ideon Tech
Read more